Match Document Document Title
7619094 Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus  
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses...
7615573 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors  
Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
7612068 Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives  
The present invention relates to compounds of formula I wherein the substituents are as defined below. The compounds of formula I are useful for the treatment of diseases such as schizophrenia,...
7608592 HCV inhibitors  
The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating...
7601752 Pyrrolidine derivatives  
The invention is concerned with novel pyrrolidine derivatives of formula (I) wherein X, Y, R 1 , R 2 and R 3 are as defined in the description and in the claims, as well as physiologically...
7601742 Pyrrolidones with anti-HIV activity  
The present invention relates to inhibition of viruses, e.g., HIV using pyrrolidones and compounds related to pyrrolidones. The invention further relates to methods for identifying and using...
7592364 Substituted gamma lactams as therapeutic agents  
Therapeutic compounds, compositions, medicaments, and methods are disclosed herein.
7592336 Hepatitis C virus inhibitors  
Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
7589119 Methods for treating or preventing metastatic cancer using benzopyranone compounds  
This invention relates to Benzopyranone Compounds, compositions comprising a Benzopyranone Compound and methods for treating or preventing cancer or inhibiting the growth of a cancer cell or...
7589118 IAP BIR domain binding compounds  
Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R 1 , R 2 , R 100 , R 200 , A, A 1 , B, B 1 , BG, n, Q and Q...
7585882 Phosphodiesterase 4 inhibitors  
Selective PDE4 inhibition is achieved by novel compounds, e.g., 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds of the present invention are of formula I: wherein R 1 , R 2 ,...
7579503 BIS (thio-hydrazide amide) salts for treatment of cancers  
Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I): Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R 1...
7579340 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists  
The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
7579320 IAP BIR domain binding compounds  
Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R 1 , R 2 , R 3 , R 100 , R 200 , R 300 , A, A 1 , BG, Q...
7576121 Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV  
The present invention is directed to pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that display selective, potent dipeptidyl peptidase IV (DPP-IV) inhibitory activity. These compounds...
7576117 Cyclic amine CCR3 antagonist  
A medicine containing, as an active ingredient, a cyclic amine derivative represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof or a...
7576102 Biaryl substituted nitrogen containing heterocycle inhibitors of LTA4H for treating inflammation  
The present invention relates to a chemical genus of biaryl substituted nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general...
7566709 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders  
Compounds of the formula (I) and salts and solvates thereof, in which X, R 1 , R 2 , R 5 and Q have the meanings indicated in Claim 1 , are suitable as ligands of 5 HT receptors; as well as...
7563910 Heterocyclic cannabinoid receptor antagonists  
The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are...
7557126 Diphenylmethyl compounds useful as muscarinic receptor antagonists  
This invention provides compounds of formula I: wherein a, b, c, e, m, n, Ar 1 , R 1 , R 2 , R 3 , R 4a , R 4b , R 5 and R 6 are as defined in the specification. The compounds of formula...
7553836 Melanin concentrating hormone receptor-1 antagonists  
The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1a , R 1b , R 1c...
7550487 Pyrrolidine-3,4-dicarboxamide derivatives  
The invention is concerned with novel pyrrolidine-3,4-dicarboxamide derivatives of formula (I) wherein R 1 to R 9 and X are as defined in the description and in the claims, as well as...
7550448 Therapeutic compounds  
Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also...
7547724 IAP BIR domain binding compounds  
Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R 1 , R 2 , R 100 , R 200 , A, A 1 , B, B 1 , BG, n, Q and Q...
7547722 Chemical compounds  
The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification, which are useful as...
7547685 Therapeutic substituted pyrrolidone compounds  
Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof are disclosed herein. Details are provided herein. Compositions, methods, and medicaments related thereto are...
7538128 Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them  
The present invention relates to novel compounds useful as dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula: wherein X, Y, a, R 1 , and R 2 are as defined herein.
7534810 Salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid  
Novel salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylet hyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptano ic acid characterized by their X-ray powder diffraction...
7531570 Treatment of diseases using ICE inhibitors  
This invention relates to methods and compositions for treating autoinflammatory diseases. The invention also assays for evaluating the ability of an ICE inhibitor to treat autoinflammatory diseases.
7528156 Compounds  
The invention provides compounds of general formula (D wherein m, n, Q, Z1, Z2, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined in the specification, processes for their preparation,...
7524859 (2-carboxamido)(3-amino)thiophene compounds  
A method of treatment of hyperproliferative disorders comprises a step of administering an effective amount of a compound represented by
7521470 Factor Xa inhibitors  
The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The...
7507767 Cannabinoid receptor ligands  
There are disclosed compounds of the formula a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit...
7504243 Methods for the production of biliverdin  
The present invention relates to compositions and methods for the production of biliverdin. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida...
RE40667 [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof  
[R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-((1-methyle thyl)-3-phenyl-4-[(phenylamino)-carbonyl)]-1H-pyrrole-1-hept anoic acid or...
7501451 Mono-acylated o-phenylendiamines derivatives  
Mono-acylated o-phenylendiamines derivatives of formula A: which are useful for the treatment of diseases mediated by the inhibition of histone deacetylase, such as cancer.
7495016 Pyrrolidones with anti-HIV activity  
The present invention relates to inhibition of viruses, e.g., HIV using pyrrolidones and compounds related to pyrrolidones. The invention further relates to methods for identifying and using...
7494988 Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease  
The present invention relates to compounds that are useful as protease inhibitors, particularly as serine protease inhibitors, and more particularly as hepatitis C NS3 protease inhibitors. As such,...
7485320 Liposome for incorporating large amounts of hydrophobic substances  
A liposome formulation for stably incorporating high content of hydrophobic substance is disclosed. The liposome includes two phospholipids with different phase transition temperatures such as...
7482374 Pyrrolidine-2-ones as Factor Xa inhibitors  
The invention relates to compounds of formula (I): wherein substituents are as defined.
7482364 Phenylalkynes  
Substituted phenylalkynes of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.
7482335 Cyclic derivatives as modulators of chemokine receptor activity  
The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis,...
7479505 Use of taurolidine to treat tumors  
The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof....
7479504 Edg receptor agonists  
The present invention encompasses compounds of Formula 1: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and...
7479502 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors  
The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these...
7476663 Substituted thiophene carboxamides  
The present invention relates to new substituted thiophene-2-carboxylic acid amides of general formula wherein A, and R 1 to R 8c are defined as in claim 1, the tautomers, the enantiomers,...
7470721 Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways  
Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.
7468443 Alkyl ether derivatives or salts thereof  
An alkyl ether derivative represented by the general formula: wherein each of R 1 and R 2 represents one or more groups selected from a hydrogen atom, a halogen atom, an alkyl group, an aryl...
7465751 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists  
This invention generally relates to the derivatives of 1-substituted-3-pyrroli dines having the structure of Formula (I): The compounds of this invention can function as muscarinic receptor...
7465718 Ansamycins having improved pharmacological and biological properties  
Ansamycins and methods of preparing and using the same are described. At least some of these ansamycins exhibit one or more of improved aqueous formulation ability, chemical stability, and...